


INFLAMMATION ANTAGONIST FOR THE TREATMENT OF **TRAUMATIC BRAIN INJURY (TBI)**




TRAUMATIC BRAN INJURY – SIGNIFICANT UNMET MEDICAL NEED



ALSP PROVIDES A SOLUTION FOR THE TREATMENT OF TBI:

INHIBITION OF CATHEPSIN B PREVENTS INFLAMMASOME ACTIVATION



CATHEPSIN B INHIBITOR IS EFFICACIOUS IN TBI MOUSE MODEL:


SINGLE DOSE < 8 HOURS FOLLOWING TBI, EFFICACY AT 7 DAYS

Efficacy Parameters:


- Preserved neuromotor function
- Preserved neuronal survival
- Reduced brain lesion volume

Hook et al (2014) J Neurotrauma

Reduced Brain Lesion Volume



Administration of Drug within 8 hours post TBI is efficacious



INTELLECTUAL PROPERTY – CATHEPSIN B INHIBITORS


US Patents

- Status - issued
- US10,022,418 (08/06/10)
- Claims
 - Compounds
 - Composition
 - Formulations

TBI MARKET SIZE (US, ANNUAL)

Initial Label

Moderate TBI



Head Injuries,
ER/Trauma Dept. visits

↓ CT Scan (+)

Hospitalization

GCS = 9-12

Severity
rating

GCS = 5-13

Moderate TBI


TM ~\$2.8B

Mild-Severe TBI

TM >\$8.4B

Label Extension

Mild-Severe TBI




RAPID ADOPTION OF ALSP's TREATMENT BY NEUROSPECIALISTS

Neurotrauma Emergency
Treatment Trials (NETT) network

Emergency Rooms / Trauma Centers

Improved Patient Prognosis




Emergency Room / Trauma Center
guidelines (P&T Committees)



Reimbursement "carve out" model
For new technology pass-through

DEVELOPMENT PLAN – BIG PICTURE

Status



Next Steps

**Additional
opportunities
and monetization**

- ▲ Label extension activities (TBI)
- ▲ 2nd indication
- ▲ Next generation Cathepsin B inhibitors

MINIMAL / NO COMPETITION

Cathepsin B inhibition	<div>ALSP Inc.</div>
Traumatic Brain Injury (TBI)	<div>ALSP Inc.</div> <div>  </div>
Inflammasome Inhibition	<div>ALSP Inc.</div> <div>      </div>

Inflammasome inhibitors, non-TBI indications

SUMMARY

Item	Take Home Messages
Indication	<ul style="list-style-type: none">• Traumatic Brain Injury (TBI); significant unmet medical need
Therapeutic Strategy	<ul style="list-style-type: none">• Inhibit Cathepsin B, prevent inflammasome activation
Preclinical Efficacy	<ul style="list-style-type: none">• Reduced brain lesion volume; neuron and brain tissue survival; preserved motor, behavioral, cognitive function
Management Team	<ul style="list-style-type: none">• Expertise in Pharma R&D, Cathepsin B, inflammasome, traumatic brain injury
Market	<ul style="list-style-type: none">• Significant market size; potential >\$B/year revenue; rapid adoption plan
Development Plan	<ul style="list-style-type: none">• Calculated timeline and budget with additional next steps and monetization